PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2895-2902

  Paz Ares, Luis G ^a   De Marinis, Filippo ^b   Dediu, Mircea ^e   Thomas, Michael ^f   Pujol, Jean Louis ⁱ   Bidoli, Paolo ^c   Molinier, Olivier ^j   Sahoo, Tarini Prasad ^l   Laack, Eckart ^g   Reck, Martin ^h   Corral, Jesús ^a   Melemed, Symantha ^m   John, William ^m   Chouaki, Nadia ^k   Zimmermann, Annamaria H ^m   Visseren Grul, Carla ⁿ   Gridelli, Cesare ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

^e Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h KRANKENHAUS GROSSHANSDORF   (Germany)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j Le Mans Regional Hospital   (France)

^k Eli Lilly France   (France)

^l Jawaharlal Nehru Cancer Hospital & Research Centre Bhopal   (India)

^m ELI LILLY AND COMPANY   (United States)

ⁿ Eli Lilly and Company   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; DEXAMETHASONE; PEMETREXED; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RISK ASSESSMENT; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GLUTAMATES; GUANINE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84885924300     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1102     Document Type: Article

References (31)

1. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
2. Brodowicz T, Krzakowski M, Zwitter M, et al: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 52:155-163, 2006
3. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
4. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
5. Pérol M, Chouaid C, Pérol D, et al: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatingemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30:3516-3524, 2012
6. Gridelli C, Maione P, Rossi A, et al: Potential treatment options after first-line chemotherapy for advanced NSCLC: Maintenance treatment or early second-line? Oncologist 14:137-147, 2009
7. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
8. Paz-Ares LG, Altug S, Vaury AT, et al: Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer 10:85, 2010
9. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
10. Belani CP, Waterhouse DM, Ghazal H, et al: Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 28: 540s, 2010 (suppl; abstr 7506)
11. D'Addario G, Früh M, Reck M, et al: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v116-v119, 2010
12. Azzoli CG, Temin S, Aliff T, et al: 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 29:3825-3831, 2011
13. Lustberg MB, Edelman MJ: Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 8:38-46, 2007
14. Socinski MA, Stinchcombe TE: Duration of first-line chemotherapy in advanced non small-cell lung cancer: Less is more in the era of effective subsequent therapies. J Clin Oncol 25:5155-5157, 2007
15. Soon YY, Stockler MR, Askie LM, et al: Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 27:3277-3283, 2009
16. Scagliotti G, Gridelli C, de Marinis F, et al: First line chemotherapy with pemetrexed plus cisplatin in advanced nonsquamous non-small cell lung cancer (NSCLC): A comparison of two phase III trials. J Thorac Oncol 6:S1160, 2011 (suppl 2; abstr P3.007)
17. Paz-Ares L, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247-255, 2012
18. Gridelli C, de Marinis F, Pujol JL, et al: Safety, resource use, and quality of life in PARAMOUNT: A phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 7:1713-1721, 2012
19. Fleming ID, Cooper JS, Henson DE: Lung, in Fleming ID, Cooper JS, Henson DE, et al (eds): AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 127-137
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
22. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), updated August 9, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm#ctc-30
23. Cox DR, Snell EJ. Analysis of binary data (ed 2). London, United Kingdom, Chapman & Hall, 1989
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1982
26. Fidias P, Novello S: Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:5116-5123, 2010
27. Behera M, Owonikoko TK, Chen Z, et al: Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. Lung Cancer 77:331-338, 2012
28. Belani CP, Wu YL, Chen YM, et al: Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: An exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. J Thorac Oncol 7:567-573, 2012
29. Ciuleanu T, Gyurkovits K, Stigt J, et al: Impact of induction chemotherapy on the outcome of treatment with pemetrexed in patients with advanced non-small-cell lung cancer: A retrospective analysis of a phase III trial. Ann Oncol 19:viii98, 2008 (suppl 8; abstr 256P)
30. Coudert B, Ciuleanu T, Park K, et al: Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 23:388-394, 2011
31. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004